Year-end Sale % OFF 
Abstract
Pirtobrutinib is a reversible non-covalent BTKi agent that is currently being evaluated in patients with a variety of B-cell malignancies, including Mantle Cell Lymphoma (MCL) (NCT03740529, BRUIN, LOXO-BTK-18001). MCL is a rare condition diagnosed in less than 3,341 people per year in the United States (U.S.). This study was designed to estimate the annual population of patients with MCL who may be eligible for treatment with pirtobrutinib in commercial and Medicare health plans in the U.S.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
